IDH2 and central nervous system cancer: In a more recent study by Suchorska et al. [75] FET PET and MRI were used to assess response to temozolomide or lomustine-based regimens in 61 patients with non-enhancing gliomas, including 19 patients with IDH-mutant, 1p/19q-non-codeleted gliomas (31%), and 30 IDH-mutant and 1p/19q-codeleted gliomas (49%).